Korlym Phase 3 Pivotal Trial–Results

homepage wave

Korlym® provided improvements in symptoms of hypercortisolism

Improved glucose control*

Improvement in oGTT glucose from baseline1

Improved glucose control graph

Korlym provided rapid and significant improvement in insulin sensitivity:
  • Reduction in AUCglucose of ≥25% in 60% of patients (assessed by oGTT)1
  • Improvement in glucose from baseline seen as early as 6 weeks (P=.004)1
  • Rapid and significant improvements in AUCinsulin, as well as demonstrated improvements in insulin sensitivity1

Reduction in HbA1c*

Mean reduction in HbA1c from baseline1,2

HbA1c Graph

Significant reduction in HbA1c of 1.1% by week 24/ET (C-DM all; ET=early termination; P<.001)
  • In a subset of patients with HbA1c >7% at baseline, a mean reduction of approximately 2% was achieved by week 242

Reduction in antidiabetic medication, including insulin1,3*

 

Additional findings included:

Significant weight loss observed*

Reduction in body weight from baseline1,4

Reduction in body weight from baseline graph

There was a significant reduction of 5.7% in mean body weight from baseline in patients treated with Korlym at week 24/ET (P<.001)1,4
  • ≥5% reduction in more than half of patients (n=24/46)1
  • ≥10% reduction in more than a quarter of patients (n=12/46)1

In addition, mean total fat mass decreased by 13.9% (P<.001).4

Significant reduction in waist circumference*

Marked decrease in waist circumference from baseline at week 24 (P<.001)1

Male gender logo

Reduction of 8.4 ± 5.9 cm for men (P<.001)1

 

Female gender logo

Reduction of 6.8 ± 5.8 cm for women (P<.001)1

†Because of the variability in clinical presentation and variability of response in this open-label study, it is uncertain whether these changes could be ascribed to the effects of Korlym.

C-DM, patients with CS and T2DM/IGT; IGT, impaired glucose tolerance; oGTT, oral Glucose Tolerance Test; T2DM, type 2 diabetes mellitus.

*Study design: SEISMIC (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing’s Syndrome) was a phase 3, uncontrolled, open-label, 24-week, multicenter clinical study of 50 subjects with endogenous Cushing syndrome. All 50 subjects had clinically significant hypercortisolism. Subjects received 300 mg to 1200 mg of Korlym per day for up to 24 weeks. Forty-three patients had Cushing disease, of which 42 had previously undergone pituitary surgery. Four patients had ectopic adrenocorticotropic hormone (ACTH) secretion, and 3 had adrenal carcinoma. Forty-six subjects received at least 30 days of dosing during the 24-week study period and were included in a modified intent-to-treat analysis.


References:

  1. Fleseriu M, Biller BMK, Findling JW, Molitch ME, Schteingart DE, Gross C; for SEISMIC Study Investigators. Mifepristone, a glucocorticoid antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049.
  2. Data on file. Corcept Therapeutics Incorporated. Menlo Park, CA.
  3. Korlym [package insert]. Menlo Park, CA: Corcept Therapeutics Incorporated; May 2017.
  4. Data on file. Corcept Therapeutics Incorporated. Menlo Park, CA.

Important Safety Information IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING ON TERMINATION OF PREGNANCY.

BOXED WARNING: TERMINATION OF PREGNANCY

Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a nonhormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.

DOSAGE AND ADMINISTRATION

Administer once daily orally with a meal. The recommended starting dose is 300 mg once daily. Renal impairment: Do not exceed 600 mg once daily. Mild-to-moderate hepatic impairment: Do not exceed 600 mg once daily. Do not use in severe hepatic impairment. Based on clinical response and tolerability, the dose may be increased in 300-mg increments to a maximum of 1200 mg once daily. Do not exceed 20 mg/kg per day.

Concomitant use of Korlym with a strong CYP3A inhibitor resulted in a 38% increase in mean plasma concentration of mifepristone. For patients already being treated with a strong CYP3A inhibitor, start with a Korlym dose of 300 mg per day and titrate to a maximum of 600 mg per day if clinically indicated. When a strong CYP3A inhibitor is administered to patients already receiving Korlym, adjust the dose as follows: For patients receiving a daily dose of 600 mg, reduce the daily dose to 300 mg. Titrate to a maximum of 600 mg per day if clinically indicated. For patients receiving a daily dose of either 900 mg or 1200 mg, reduce the daily dose to 600 mg.

CONTRAINDICATIONS

Pregnancy; use of simvastatin or lovastatin and CYP3A substrates with narrow therapeutic range; concurrent long-term corticosteroid use; women with history of unexplained vaginal bleeding; women with endometrial hyperplasia with atypia or endometrial carcinoma.

WARNINGS AND PRECAUTIONS

Adrenal insufficiency: Patients should be closely monitored for signs and symptoms of adrenal insufficiency.

Hypokalemia: Hypokalemia should be corrected prior to treatment and monitored for during treatment.

Vaginal bleeding and endometrial changes: Women may experience endometrial thickening or unexpected vaginal bleeding. Use with caution if the patient also has a hemorrhagic disorder or is on anticoagulant therapy.

QT interval prolongation: Avoid use with QT interval-prolonging drugs, or in patients with potassium channel variants resulting in a long QT interval.

Use of strong CYP3A inhibitors: Concomitant use increases mifepristone plasma levels. Adjust Korlym dose as described in Dosage and Administration. Use only when necessary and do not exceed a Korlym dose of 600 mg.

ADVERSE REACTIONS

Most common adverse reactions in Cushing’s syndrome (≥20%): nausea, fatigue, headache, decreased blood potassium, arthralgia, vomiting, peripheral edema, hypertension, dizziness, decreased appetite, endometrial hypertrophy.

DRUG INTERACTIONS

Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest dose when used with Korlym.

CYP3A inhibitors: Caution should be used when Korlym is used with strong CYP3A inhibitors. Adjust Korlym dose as described in Dosage and Administration. Use only when necessary, and do not exceed a Korlym dose of 600 mg.

CYP3A inducers: Do not use Korlym with CYP3A inducers.

Drugs metabolized by CYP2C8/2C9: Use the lowest dose of CYP2C8/2C9 substrates when used with Korlym.

Drugs metabolized by CYP2B6: Use of Korlym should be done with caution with bupropion and efavirenz.

Hormonal contraceptives: Do not use with Korlym.

USE IN SPECIFIC POPULATIONS

Nursing mothers: Discontinue drug or discontinue nursing.

Please see accompanying full Prescribing Information and Medication Guide.

INDICATIONS AND USAGE

Korlym® (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Important Limitations of Use

Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing’s syndrome.